Quest for the right Drug
מוביפרפ ® MOVIPREP ® (ASCORBIC ACID, MACROGOLS, POTASSIUM CHLORIDE, SODIUM ASCORBATE, SODIUM CHLORIDE, SODIUM SULFATE ANHYDROUS)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
אבקה להכנת תמיסה : POWDER FOR SOLUTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Special Warning : אזהרת שימוש
4.4 Special warnings and precautions for use Diarrhoea is an expected effect resulting from the use of Moviprep. Moviprep should be administered with caution to fragile patients in poor health or patients with serious clinical impairment such as: - impaired gag reflex, or with a tendency to aspiration or regurgitation - impaired consciousness - severe renal insufficiency (creatinine clearance <30mL/min) - cardiac impairment (NYHA grade III or IV) - those at risk of arrhythmia, for example those on treatment for cardiovascular disease or who have thyroid disease - dehydration - severe acute inflammatory bowel disease The presence of dehydration should be corrected before the use of Moviprep. The fluid content of Moviprep when re-constituted with water does not replace regular fluid intake and adequate fluid intake must be maintained. Semi-conscious patients or patients prone to aspiration or regurgitation should be closely observed during administration, especially if this is via a nasogastric route. In patients with swallowing problems, who need the addition of a thickener to solutions to enhance an appropriate intake, interactions should be considered, see section 4.5. If patients develop any symptoms indicating arrhythmia or shifts of fluid/electrolytes (e.g. oedema, shortness of breath, increasing fatigue, cardiac failure), plasma electrolytes should be measured, ECG monitored and any abnormality treated appropriately. In debilitated fragile patients, patients with poor health, those with clinically significant renal impairment, arrhythmia and those at risk of electrolyte imbalance, the physician should consider performing a baseline and post-treatment electrolyte, renal function test and ECG as appropriate. There have been rare reports of serious arrhythmias including atrial fibrillation associated with the use of ionic osmotic laxatives for bowel preparation. These occur predominantly in patients with underlying cardiac risk factors and electrolyte disturbance. If patients experience symptoms such as severe bloating, abdominal distention, abdominal pain or any other reaction which makes it difficult to continue the preparation, they may slow down or temporarily stop consuming Moviprep and should consult their doctor. Ischaemic colitis Post-marketing cases of ischaemic colitis, including serious, have been reported in patients treated with macrogol for bowel preparation. Macrogol should be used with caution in patients with known risk factors for ischaemic colitis or in case of concomitant use of stimulant laxatives (such as bisacodyl or sodium picosulfate). Patients presenting with sudden abdominal pain, rectal bleeding or other symptoms of ischaemic colitis should be evaluated promptly. This medicinal product contains 363.2 mmol (8.4 g) sodium per course of treatment equivalent to 420% of the of the WHO recommended maximum daily intake of 2 g sodium for an adult. (A course of treatment consists of two litres of Moviprep). To be taken into consideration by patients on a controlled sodium diet. Only a proportion (up to 112.4 mmol (2.6 g) per course treatment) of sodium is absorbed. This medicinal product contains 28.4 mmol (1.1 g) potassium per course of treatment. (A course of treatment consists of two litres of Moviprep). To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet. The medicinal product contains aspartame, which is a source of phenylalanine. This may be harmful for people with phenylketonuria.
Effects on Driving
4.7 Effects on ability to drive and use machines Moviprep has no influence on the ability to drive and use machines.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
23/01/2011
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
יצרן
NORGINE LIMITED, UKבעל רישום
PADAGIS ISRAEL AGENCIES LTD, ISRAELרישום
145 38 33156 00
מחיר
0 ₪
מידע נוסף
עלון מידע לצרכן
20.12.16 - עלון לצרכן אנגלית 22.07.21 - עלון לצרכן אנגלית 22.07.21 - עלון לצרכן עברית 20.12.16 - עלון לצרכן ערבית 22.07.21 - עלון לצרכן ערבית 12.10.22 - עלון לצרכן עברית 29.11.22 - עלון לצרכן אנגלית 29.11.22 - עלון לצרכן עברית 29.11.22 - עלון לצרכן ערבית 08.06.23 - עלון לצרכן עברית 24.08.23 - עלון לצרכן אנגלית 25.08.23 - עלון לצרכן אנגלית 24.08.23 - עלון לצרכן ערבית 24.08.23 - עלון לצרכן ערבית 03.11.24 - עלון לצרכן עברית 20.05.12 - החמרה לעלון 20.05.12 - החמרה לעלון 08.11.15 - החמרה לעלון 12.01.21 - החמרה לעלון 05.04.21 - החמרה לעלון 22.07.21 - החמרה לעלון 11.10.22 - החמרה לעלון 12.10.22 - החמרה לעלון 07.03.23 - החמרה לעלון 08.06.23 - החמרה לעלון 26.01.24 - החמרה לעלון 05.11.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
מוביפרפ ®
